Searched for
CHUDGARS OF INTAS
Intas Pharma completes acquisition of UDENYCA biosimilar for $558 millionIntas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. ...- Biosimilar brand buy to help Intas Pharma take on biggiesIn one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication peg...
- Intas in pact with Spanish drug maker mAbxience to sell biosimilar etanercept in over 150 countriesmAbxience, a majority-owned company of German drug maker Fresenius Kabi, also has partial ownership from Insud Pharma, will be responsible ...
- Abu Dhabi Sovereign Fund to buy into Intas PharmaADIA, with assets under management worth $800 billion, has a wide exposure in India. Its major investments include Flipkart, Reliance Retai...
- Intas to provide 2 million hydroxychloroquine tablets for WHO study on COVID-19Intas informed that it is collaborating on the WHO-endorsed study using hydroxychloroquine, a drug that may have an effect in preventing an...
- Intas low-balls Mallinckrodt unit bid to $1bn on legal fearsLast year, media reports mentioned that Intas had emerged as a strong contender to acquire Mallinckrodt unit in a deal estimated between $1...
- Intas closing in on Mallinckrodt’s US generics businessThis comes as US President Donald Trump has declared opioid addiction a public health emergency in the US and drugmakers have found themsel...
- Intas eyes Teva’s oncology, women’s health divisions in EuropeTeva, the world’s largest maker of generic drugs, plans to divest some assets including its global women’s health and European cancer and p...
- ChrysCapital sells 3% in Intas to Capital InternationalChrysCapital will continue to hold a 3% stake in Intas, making it the longest and probably the most successful private equity investment in...
- Chudgars of Intas: A family that dreams big togetherTrumping bigger rivals Aurobindo, Intas shot into the limelight on Wednesday, scooping up Teva's assets in the UK and Ireland in a $764 mil...
- Intas buys Teva's UK & Ireland assets for $764 million to break into global top 20 generic players clubWith the acquisition of Teva’s products, sold through erstwhile Actavis’ operations, Intas is set to emerge as a top player in the UK gener...
- Intas Pharmaceuticals to launch its first biosimilar in US in 9-12 monthsIntas is the only domestic firm with two biosimilars filed for registration in the US and it looks to deliver affordable and innovative pha...
- Intas Pharma launches its first biosimilar product Accofil in EuropeThe product has recently been introduced under the brand Accofil and has already won two prestigious tenders, in Netherlands and the UK.
- Intas Pharmaceuticals sells ChrysCapital’s stake to TemasekIntas Pharmaceuticals Ltd has announced that Singapore investment company Temasek has acquired a 10.16% equity stake in the company.
- Temasek completes 10.16% stake purchase in Intas PharmaTemasek acquired the stake by way of secondary purchase of shares from private equity investor ChrysCapital. This investment will deepen Te...
- Open to acquisition, can spend up to $100 million: Binish Chudgar, Intas PharmaceuticalsIntas Pharmaceuticals is not ignoring the local market where it plans to be among the top five players by 2015, vice-chairman and MD Binish...
- ChrysCap to buy Rs 300-cr stake in Intas PharmaceuticalsPrivate equity firm ChrysCapital is buying an additional stake in Intas Pharmaceuticals for Rs 300 crore after the Ahmedabad-based drug mak...
- ChrysCapital set to raise stake in Intas Pharmaceuticals ahead of deferred IPOAlthough the stake could not be be confirmed, the pre-IPO deal will increase ChrysCapital's holding in the company to over 15% from 11.3% c...
- ChrysCapital, Blackstone and Advent Capital in race to buy stake in Intas Pharma for Rs 250 crore3 PE firms are vying for a minority stake in generic drugmaker Intas Pharmaceuticals, two people familiar with the development told ET.
- Intas Pharma IPO to raise Rs 800 cr, fund acquisitionsIntas Pharma plans to raise Rs 750-800 cr through IPO that will help it raise fresh funds for acquisitions besides allowing PE investor Chr...
Load More
